Siolta Therapeutics, a San Carlos, CA-based clinical-stage biotech company, raised $12M in Series C funding.
The round was led by SymBiosis and Khosla Ventures, with participation of existing investors.
The company intends to use the funds for the further clinical development of it lead product, STMC-103H, and for support a collaboration with Johns Hopkins University to help select the clinical candidate to be evaluated in future trials.
Led by CEO Dr. Nikole E. Kimes, Siolta Therapeutics is a clinical-stage biotech company developing defined-consortia live biotherapeutic products that target the core drivers of disease. By leveraging its proprietary precision symbiotics platform™, Siolta advanced multiple programs into clinical and preclinical development. Its lead program, STMC-103H, is in phase 2 development for the prevention of atopic diseases, including atopic dermatitis, food allergy, and asthma. The company is also advancing two preclinical programs, STMC-105 and STMC-106, targeting recurrent bacterial vaginosis and necrotizing enterocolitis indications for which no FDA-approved products exist.
Commenting on the news, Nikole E. Kimes said: “This Series C financing is a key step for Siolta as we continue to develop STMC-103H in the clinic. We are excited to push the boundaries of current therapeutic development, pursuing a transformative approach that targets the underlying cause of disease, and we are committed to bringing safe and effective treatment options to patients. We appreciate the ongoing support of our investors, which is critical in our efforts to fulfill our mission.”
FinSMEs
13/03/2024